20th Aug 2015 07:47
LONDON (Alliance News) - Pharmaceutical manufacturer, developer and supplier Quantum Pharma PLC on Thursday said it is trading in line with market expectations for the full year, though some of its licence applications are taking longer than anticipated.
Quantum said it has now completed the acquisitions of Lamda and NuPharm Group and is confident both will prove successful going forward. Colonis, its specialist pharmaceutical product development arm, has continued to grow its pipeline and is making progress on its product launch programme.
But while the company said it remains confident licences will be secured for all the products for which it has entered submissions, the process for a small number of applications made earlier in the year is taking longer than expected.
Quantum will publish its half-year results, for the six months to the end of July, on October 20.
Shares in Quantum were down 5.7% to 140.00 pence on Thursday.
By Sam Unsted; [email protected]; @SamUAtAlliance
Copyright 2015 Alliance News Limited. All Rights Reserved.
Related Shares:
Quantum Pharma